Background The emergence of programmatically incurable tuberculosis threatens to destabilise control eff orts. The aim of this study was to collect prospective patient-level data to inform treatment and containment strategies.
Introduction
Resistance to antituberculosis drugs has emerged as a serious and pressing global health concern.
1 During the past decade, widespread resistance to rifampicin and isoniazid (multidrug resistance) has been supplanted by additional resistance to fl uoroquinolones and the secondline injectable drugs amikacin, kanamycin, and capreomycin (extensive drug resistance), 2, 3 and now resistance beyond extensive drug resistance (known as totally drug-resistant tuberculosis, a non-standardised defi nition) has emerged. 4 Multidrug-resistant and extensively drugresistant tuberculosis drive roughly a quarter of global tuberculosis mortality, 1 are unsustainably costly to treat, [5] [6] [7] [8] and pose a major threat to health-care workers. 9 In 2014 there were almost 500 000 cases of multidrugresistant tuberculosis globally, and 18 734 reported cases of rifampicin-resistant or multidrug-resistant tuberculosis in South Africa (of which roughly 8% were thought to be extensively or totally drug resistant). 10, 11 Further resistance to the drugs used to treat extensively drug-resistant disease has resulted in patients for whom a treatment regimen cannot be constructed with the drugs available in the national programme and who thus have programmatically untreatable tuberculosis. 4, 10, 12, 13 Estimates from Africa, Russia, India, and China suggest that treatment fails to cure 30-75% of patients with extensively or totally drugresistant tuberculosis. [14] [15] [16] [17] [18] New drugs such as bedaquiline, 19, 20 and repurposed ones such as linezolid, [21] [22] [23] have become available in some settings. However, in many countries access is severely limited and the inability to construct an eff ective regimen using at least four eff ective drugs (despite the availability of newer agents) has rendered many patients impossible to treat eff ectively. Patients in whom treatment has failed are often discharged to home care in the community. 4 The epidemiology and long-term outcomes beyond 2 years for these patients have not been comprehensively and prospectively studied, and potentially eff ective drug combinations for such cases of treatment failure remains unclear. Furthermore, the capacity of these patients to transmit disease is not known, and although
Research in context
Evidence before this study Reports of programmatically incurable tuberculosis (cases of treatment failure in extensively drug-resistant tuberculosis) have come from countries with a high tuberculosis burden, including China, India, and South Africa. The poor cure rates, high economic cost, and drain on scarce resources of treatment for drug-resistant tuberculosis threatens to destabilise tuberculosis control eff orts in aff ected countries. We searched PubMed for articles published in all languages up to Aug 1, 2016, with the terms "XDR-TB" or "XDR-TB" and "treatment failure" and "outcome". Of 44 articles identifi ed, ten described treatment failure in extensively drug-resistant tuberculosis, two of which concerned the same cohort. Only one study followed up cases of treatment failure to document duration to hospital discharge and post-discharge outcomes including survival. This South African study described a short prospective follow-up of a retrospectively selected cohort and post-discharge outcomes in only 19 cases of treatment failure in extensively drug-resistant tuberculosis. Median survival of patients who had failed treatment from time of discharge was 19·84 months (IQR 4·16-26·04). Infectiousness and transmission dynamics to elicit the magnitude of community-based transmission was not undertaken. No further articles reporting follow-up of treatment failure in extensively drug-resistant tuberculosis were identifi ed. Similarly, a search of PubMed using the terms "XDR" or "MDR" and "TB" and "infectiousness" revealed no studies assessing the infectiousness of individual patients with drug-resistant tuberculosis.
Added value of this study
We describe a large prospective study of clinical outcomes and longevity in home-discharged patients with tuberculosis resistant to fi rst-line and second-line drugs and for whom a curative treatment regimen was not available. More importantly, to our knowledge, our data about respirable aerosols infected with Mycobacterium tuberculosis expelled during coughing in this study are the fi rst to describe the infectiousness of individual patients with programmatically incurable tuberculosis. The accompanying whole-genome sequencing data from M tuberculosis isolates provides evidence of transmission and post-discharge generation of secondary cases in the community with high mortality. Previous study fi ndings have suggested nosocomial transmission of extensively drug-resistant tuberculosis, but here we provide evidence that highly drug-resistant strains are spreading in the community from home-discharged patients and generating secondary cases with poor outcomes. These data challenge previously held assumptions that highly drug-resistant mycobacteria have reduced fi tness and diminished capacity to infect new patients. Our fi ndings also show that, although survival is poor, patients can reside in the community for months or years after discharge home and before death. Evidence presented for regimens likely to be eff ective include the description of rifabutin-sensitive cases despite resistance to rifampicin.
Implications of all the available evidence
Evidence from this large, prospective study shows that home-discharged patients with infectious, highly drug-resistant tuberculosis survive for considerable periods of time and, more importantly, are a source of transmission, which has serious implications for public health. Previous evidence of nosocomial transmission of extensively drug-resistant tuberculosis, such as the outbreak associated with an HIV clinic in Tugela Ferry, demonstrate the crucial importance of infection control. Our fi ndings highlight an urgent need to interrupt transmission in communities. The increasing incidence of extensively drug-resistant tuberculosis reported by WHO and reports of programmatically incurable tuberculosis from countries such as China and India indicate that such patients are not unique to South Africa. Investment is urgently needed to halt the rise of programmatically incurable tuberculosis that risks taking us back to the pre-antibiotic era. Cure rates are enhanced by use of the new and repurposed drugs (bedaquiline, delamanid, and linezolid) but are hampered by their lack of availability in many countries. Poor access to drug susceptibility tests and empirical treatment of drug-resistant disease risks amplifi cation of resistance when a curative regimen might no longer be possible. Thus, the available evidence indicates an urgent need to rollout new drugs and drug resistance testing, reduce opportunities for transmission, and facilitate care for individuals with highly resistant and incurable tuberculosis when discharged from hospital.
the transmission of drug-resistant bacteria is thought to be attenuated compared with susceptible bacteria, 24 the detection of drug-resistant tuberculosis has increased in several high-burden countries, and serious epidemics are unfolding in others including South Africa, India, Russia, and several countries in eastern Europe and central Asia. 25 To interrogate these questions, we did a long-term prospective study in patients with extensively drugresistant tuberculosis who received treatment regimens based on aminosalicylic acid, capreomycin, or both according to prevailing national guidelines at the time. We postulated that a substantial proportion of homedischarged patients with extensively drug-resistant tuberculosis that had not responded to treatment would remain infectious and generate secondary cases of extensively drug-resistant tuberculosis in the community. We thus undertook whole-genome sequencing of baseline Mycobacterium tuberculosis culture isolates and did cough aerosol sampling to quantify the infectiousness of individual patients.
Methods

Study design and participants
Between Oct 1, 2008, and Oct 31, 2012, we recruited all adult patients with microbiologically confi rmed, extensively drug-resistant tuberculosis (defi ned as resistance to at least rifampicin, isoniazid, a fl uoroquinolone, and a second-line injectable) who were admitted to two South African treatment facilities (Brooklyn Chest Hospital, Western Cape, and Harry Surtie [previously Gordonia] Hospital, Northern Cape; fi gure 1A). Both hospitals are designated specialist referral centres for the treatment of all patients diagnosed with extensively drug-resistant tuberculosis within their province. All patients with extensively drug-resistant tuberculosis who initiated treatment were admitted to the designated hospitals during the study period and received a treatment regimen based on aminosalicylic acid, capreomycin, or both according to prevailing national guidelines at the time (linezolid and bedaquiline were not available within the tuberculosis programme). Patients were followed up until Oct 31, 2014 (the study censor date), or death. Patients were reviewed in hospital and data was captured on a quarterly basis by a trained researcher using a standardised case record form. Discharged patients were contacted by telephone and visited at their homes, and treatment in the continuation phase was directly observed. Sputum samples were collected monthly for smear microscopy and culture. Further laboratory and clinical investigations were done only on patients or samples from Brooklyn Chest Hospital in the Western Cape (n=204) and were dependent on the availability of samples. This included extended drug susceptibility testing to 18 drugs (rifampicin, isoniazid, amikacin, kanamycin, streptomycin, cycloserine, ethionomide, ethambutol, moxifl oxacin, ofl oxacin and aminosalicylic acid, capreomycin, dapsone, clarithromycin, clofazimine, linezolid, pyrazinamide, and rifabutin; n=179), next-generation whole-genome sequencing (n=153), and cough aerosol sampling (n=26; fi gure 1B). Thus, further investigations were not undertaken on patients or samples from the Harry Surtie Hospital in the Northern Cape.
Ethical approval was obtained from the University of Cape Town Human Research Ethics Committee and participants provided informed written consent.
Procedures
A 5-year study period, including recruitment and follow-up, was selected to enable the recruitment of a sizable cohort and to allow for the assignment of programmatic treatment outcomes. Treatment duration for extensively drug-resistant tuberculosis is 24 months, and therefore at least 2 years of follow-up are required. We routinely recorded death during follow-up (table, fi gure 2). We additionally recorded programmatic treatment outcomes at 24 months and 60 months, including death, as outlined in the WHO defi nitions and reporting framework (adapted when appropriate; appendix p 10). 26 We also assessed the proportion of patients who were cured, completed treatment, had treatment failure, died while on treatment, relapsed, defaulted, and had ongoing treatment. In patients who were discharged home, we defi ned death while on treatment as deaths in patients who were receiving futile treatment (token oral treatment with one or two oral agents [eg, pyrazinamide and ethambutol] was often given for perceived humanitarian reasons by the clinician in charge). Clinical primary disease was defi ned as any patient with at least one of the following: no previous tuberculosis episode, drug-susceptible tuberculosis cured more than 12 months before the current diagnosis, fi rst empirical treatment for drugsusceptible tuberculosis 9 months or less before the current diagnosis, or pre-extensively drug-resistant tuberculosis (resistance to rifampicin, isoniazid, and either a fl uoroquinolone or an aminoglycoside) 6 months or less before the current diagnosis (full defi nitions are given in the appendix, p 11). Capreomycin was prescribed according to the national guidelines because linezolid and bedaquiline were not available within the national tuberculosis programme at the time. Capreomycin was used even when isolates were phenotypically resistant, due to the paucity of other therapeutic options and the drug's high serum to minimum inhibitory concentration ratio (thus possibly still providing therapeutic benefi t). Further details of methodology are presented in the appendix (p 6).
Drug susceptibility testing
Phenotypic drug susceptibility testing was done by the National Health Laboratory Service in accordance with the national tuberculosis programme guidelines; included second-line drugs were ofl oxacin, amikacin, ethionamide, and (in a subset of patients, at the request of the attending clinician) capreomycin. Additional testing was done on See Online for appendix 186 available isolates from Brooklyn Chest Hospital using Sensititre MYCOTB MIC plates (Trek Diagnostic Systems, Cleveland, OH, USA) to establish minimum inhibitory concentrations for rifampicin, isoniazid, amikacin, kanamycin, streptomycin, cycloserine, ethionomide, ethambutol, moxifl oxacin, ofl oxacin, and aminosalicylic acid. Resistance to capreomycin, dapsone, clarithromycin, clofazimine, linezolid, pyrazinamide, and rifabutin was determined using the BD BACTEC mycobacterial growth indicator tube (MGIT; Becton Dickinson Diagnostic Systems, Sparks, MD, USA; further details are provided in the appendix, p 6). Sensititre or MGIT results were used in analyses if discrepancies were observed compared with programmatic drug susceptibility testing. We did a secondary analysis excluding discrepant patients to rule out possible bias from misclassifi ed samples.
Further investigations were not undertaken in patients from the Northern Cape province because of logistical (inability and lack of approval to transport highly infectious material) and regulatory (provincial and ethical approvals could not be obtained) reasons.
Genome analysis
We used IS6110 restriction fragment length polymorphism (RFLP) fi ngerprinting to assess available M tuberculosis MGIT cultures from the sputum of patients from Brooklyn Chest Hospital (n=165). 27 We did whole-genome sequencing on extracted DNA (n=153; more details are provided in the appendix, p 7) using Illumina HiSeq2000 technology (available at European Nucleotide Archive with accession PRJEB14199). 28 The data processing pipeline that we used has been described previously. 29 We mapped SNP=single nucleotide polymorphism. *Four samples failed quality control for genotypic drug resistance analysis; of the remaining 149 readouts, 141 passed quality control for SNP analysis. Of these, 90 were from isolates belonging to home-discharged cases; thus, there were 90 home-discharged cases that had isolates with valid whole-genome sequences. †Cough aerosol sampling was done after diagnosis of extensively drug-resistant tuberculosis, but not necessarily exactly 6 months after diagnosis. Phenotypic drug susceptibility testing was done at the time of cough aerosol sampling in 20 patients. Contact reporting was assessed in 13 patients who underwent cough aerosol sampling. To calculate the number of SNPs diff ering between isolates, we fi rst removed all mutations associated with drug resistance, then clustered isolates by lineage, and fi ltered out isolates with a proportion of missing calls greater than 10%. Positions where any isolate in a cluster had a missing call were removed and the number of SNPs diff ering between two isolates were calculated. Finally, we compared mutations associated with drug resistance between isolates. This process was repeated within each cluster until no further separation was observed. We used a threshold of fi ve or fewer SNP diff erences and identical markers of drug resistance in genes encoding for 14 drugs (amikacin, capreomycin, ethambutol, ethionamide, fl uoroquinolones, isoniazid, kanamycin, aminosalicylic acid, pyrazinamide, rifampicin, streptomycin, linezolid, bedaquiline, clofazimine) when assigning transmission events. 30, 31 Phylogenetic trees and interaction networks were created using the R packages ape (v 3.3) and qgraph (v1.3.1), respectively.
Genotypic drug resistance
Samples with inadequate sequence coverage of the genes responsible for resistance to rifampicin and isoniazid were removed from the analysis. Variants were analysed against known resistance markers and resistanceconferring genes for each of the major antituberculosis drugs 32 33 Isolates with less than ten-depth coverage or a low confi dence structural variant at a resistant marker and no positive resistant marker for the drug under investigation were excluded. For rifabutin, mutations at codon 516* (Asp526Thr/Ser/Val) in rpoB (Rv0667) were removed because they do not increase the minimum inhibitory concentration of rifabutin to above the critical threshold of 0·5 μg/mL. 34 Similarly, the naturally occurring variant Arg409Gln in Rv1979c (clofazimine resistance gene) was excluded.
Cough aerosol sampling
The cough aerosol sampling system is a newly validated technology; its readings positively correlate with tuberculin skin test conversion and incident tuberculosis in household contacts of index patients with active tuberculosis. 35 A cough aerosol sampling system was installed at Brooklyn Chest Hospital towards the end of the study (February, 2013) , and was thus only done on a subset of 26 patients admitted to Brooklyn Chest Hospital. The system enumerates culturable, respirable cough aerosol particles (<5 μm; able to reach the alveolar compartment) to assess the infectiousness of individual patients. [36] [37] [38] Briefl y, patients were asked to cough into a sterile chamber containing a six-stage Andersen cascade impactor (Thermo Scientifi c, Rockford, IL, USA) that collects airborne particles of known size distribution (appendix p 8). Patients coughed as frequently as was comfortable for two 5 min sessions, separated by a rest of approximately 5 min. Cough aerosol particles were deposited on 7H11 media (BD Biosciences, San Jose, CA, USA), supplemented with Mycobacteria Selectatab (Kirchner Mast Group, Merseyside, UK). Colony-forming units of M tuberculosis from droplets in the respirable range were recorded after incubation at 37°C. Sputum specimens collected during the cough aerosol sampling system visit were processed for smear microscopy, culture, and phenotypic drug susceptibility testing. After sampling, patients were provided with surgical facemasks and requested to report mask usage and contact with other individuals. Kaplan-Meier survival estimates for probability of survival (A) Survival since diagnosis in all patients with extensively drug-resistant tuberculosis, stratifi ed by HIV status (n=272; one patient refused testing and was not included in this analysis). (B) Survival since discharge from hospital for home-discharged patients stratifi ed by favourable vs unfavourable outcomes (n=148; 172 patients were discharged home but patients who were lost to follow-up and transferred out were not included in this analysis). Unfavourable outcomes are divided into treatment default, treatment failure with no further therapy (death while on no treatment), and treatment failure with death while receiving ineff ective treatment after discharge. (C) Survival since discharge from hospital for home-discharged patients by type of unfavourable outcome (treatment failed and not on therapy, defaulted and not on therapy, or death while on treatment; n=144 [two patients relapsed and two patients had ongoing treatment, so were not included in this analysis]). HRs were calculated vs a favourable outcome (ie, cure or treatment completion; n=42). (D) Survival since discharge from hospital in home-discharged patients with unfavourable outcomes stratifi ed by smear status at discharge (n=104). HR=hazard ratio. XDR-TB=extensively drug-resistant tuberculosis. *HR 6·82 (95% CI 2·29-20·31); p=0·00056. †HR 18·59 (95% CI 6·61-52·33); p<0·0001. ‡HR 52·54 (95% CI 16·75-164·982; p<0·0001. 
A
Statistical analysis
We calculated medians and IQRs for continuous variables and frequency (percent) for categorical variables. We compared continuous variables with Wilcoxon rank sum tests and categorical variables with χ² tests. Kaplan-Meier curves were estimated for the probability of survival either from date of diagnosis or date of discharge. End of follow-up was date of death, date of loss to follow-up, or censor date. Comparisons between strata (eg, HIVinfected vs HIV-uninfected individuals) were made by the log-rank test. Univariate Cox proportional hazards models were used to estimate the relation between explanatory variables and time-to-event outcomes. We included the variables of HIV status, antiretroviral therapy status, sex, race, treatment outcome (favourable or unfavourable), M tuberculosis lineage, smoking, education, weight at diagnosis, age at diagnosis, number of drugs prescribed, history of tuberculosis, and history of multidrug-resistant tubercu losis, and a binary variable for each of the drugs prescribed. Multivariate Cox proportional hazards models for mortality included variables that were signifi cantly associated with outcome (p<0·1) and the prespecifi ed variables (sex, race, education, HIV status). We used a 90% threshold so that we would not exclude variables that, although not signifi cant at an alpha of 0·05 in univariate analysis, might be signifi cant in a multivariate analysis. The underlying proportional hazards assumption was assessed using the (weighted) scaled Schoenfeld residuals test. We regarded p values as statistically signifi cant at a nominal value of p<0·05, but in view of the large number of exploratory outcomes signifi cance should not be taken as confi rmatory. Thus, patients were included in the analysis that were still in the study at the time the measurement under investigation was taken, and for whom a result was available, even if they were later lost to follow-up. Statistical analysis was done in in R (version 3·0) and graphics generated with the package ggplot2.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. KD, JDL, EP, and RM had full access to the raw data. The corresponding author had full access to all of the data and the fi nal responsibility to submit for publication.
Results
273 patients, 204 (75%) from Brooklyn Chest Hospital and 69 (25%) from Harry Surtie Hospital, were recruited into the study. Patient demographics are summarised in the table and the appendix (p 15). 119 (44%) patients had HIV, with a median CD4 cell count of 199·5 cells per μL (IQR 85·8-323·0). All but fi ve patients with HIV were on antiretroviral therapy. We noted clinically defi ned, primary tuberculosis with extensive drug-resistance in 91 (33%) patients.
The median duration of follow-up was 20·3 months (IQR 9·6-27·8). At censor date, 186 (68%) patients had died (table). 203 (74%) patients had unfavourable treatment outcomes (treatment failure, treatment default, relapse, or death while on treatment; appendix p 16), and thus programmatically incurable tuberculosis. Multivariate analysis showed that bodyweight of 50 kg or more (p<0·0001), increased time to culture positivity (p<0·0001), increased age at diagnosis (p=0·004), and treatment with aminosalicylic acid (p=0·001) were associated with survival (appendix p 19).
172 (63%) patients were home discharged from hospital into the community; patient outcomes are summarised in the appendix (p 25). 53 (31%) of these patients had died in the fi rst 12 months after discharge and 89 (52%) had died by the end of study. Unfavourable outcomes occurred in 104 (60%) of home-discharged patients (appendix p 25) with treatment failing in 54 (31%); 43 (80%) of these patients later died. Their median time to death after homedischarge was 9·9 months (IQR 4·2-17·4). Positive sputum smear results were recorded for 35 (20%) of homedischarged patients a median of 21·0 days (IQR 10·5-36·0) from discharge, and were associated with reduced longevity (fi gure 2).
We noted high levels of drug resistance for fi rst-line and second-line drugs (fi gure 3, appendix p 13). For logistical and regulatory reasons, phenotypic drug susceptibility testing to 18 antitubercu losis drugs was done only on patient isolates from Brooklyn Chest Hospital, accounting for 179 (66%) of the total cohort (fi gure 1B). 135 (75%) patients were resistant to eight or more drugs, 77 (43%) were resistant to ten or more drugs, and four (2%) were resistant to a maximum of 13 drugs.
Whole-genome sequencing of the 149 isolates that passed quality control for genotypic drug resistance analysis showed few mutations associated with resistance to new, novel, and repurposed drugs (fi gure 3, appendix p 20). One isolate had an Ser68Asn mutation in the Rv0678 gene, thought to be likely predictive of bedaquiline resistance. 39 SNP analysis suggested susceptibility to rifabutin in 34 (23%) of the 149 extensively drug-resistant tuberculosis isolates sequenced; confi rmatory phenotypic drug susceptibility testing was done with the MGIT 960 system and 32 (97%) of 34 isolates were rifabutin sensitive at a critical concentration of 0·5 μg/ml. Of the 31 homedischarge cases with whole-genome sequencing data, fi ve (16%) were confi rmed as rifabutin-sensitive. Importantly, 19 of the confi rmed rifabutin-sensitive cases were in patients with unfavourable treatment outcomes (11 were home discharged and living in the community for a mean of 21·0 months [SD 14·2]).
Phenotypic analysis of sequential isolates collected at least 6 months after the initial diagnostic isolate showed that one (3%) of 34 isolates gained resistance to clofazimine (the patient did not receive clofazimine), six (21%) of 29 isolates gained resistance to dapsone (two of the six patients had received dapsone), and four (67%) of six isolates gained resistance to capreomycin (all four patients received capreomycin; appendix p 21). Of the 26 sequential isolate pairs examined by whole-genome sequencing, three (50%) of six patients who received capreomycin gained drug-specifi c resistance mutations (appendix p 22).
Whole-genome sequencing was performed on 153 diagnostic patient isolates from Brooklyn Chest Hospital in the Western Cape (fi gure 1). Genotyping these isolates revealed lineage 2 (Beijing) strains to be dominant (appendix p 23). Genome sequences from 141 isolates passed quality control measures for SNP analysis. 16 (11%) of these isolates had evidence suggestive of heteroresistance (both wildtype and drug-resistance-conferring mutations). 11 had evidence of mixed infection (ie, more than one strain of M tuberculosis), two of which had evidence of heteroresistance.
Using longitudinal samples from our cohort, we calculated the median number of SNPs accumulated per isolate genome per year as 0·99 (95% CI 0·79-1·67), which translates into a fi ve-SNP change (using the lower confi dence limit) occurring over 38 months, compared with a median diagnostic time diff erence between any two patients with extensively drug-resistant tuberculosis of 14·1 months (IQR 6·4-23·3).
Interpatient comparisons showed substantial similarity between isolates. The proportion of isolates diff ering by one or fewer, two or fewer, or fi ve or fewer SNPs from at least one other patient isolate while having identical genotypic drug resistance profi les were 25 (18%) of 141, 41 (29%) of 141, and 65 (46%) of 141, respectively (appendix p 24). 46 (18%) of 273 patients self-reported exposure to tuberculosis before their diagnosis and 12 (4%) self-reported exposure to individuals with known extensively drugresistant tuberculosis. Whole-genome sequencing or IS6110-RFLP data were available for six patient-contact pairs (appendix p 25). Whole-genome sequencing and RFLP data suggested transmission (fi ve or fewer SNPs diff erent, identical IS6110-RFLP patterns) in four of fi ve cases with data available; in one case for which wholegenome sequencing data were unavailable, we noted identical IS6110-RFLP patterns (appendix p 25).
Isolates from 37 (41%) of the 90 home-discharged patients from Brooklyn Chest Hospital with whole-genome sequencing data available were highly similar and clustered (fi ve or fewer SNPs diff erent and with identical resistanceencoding mutations for 14 drugs; fi gure 4). The median time spent by these patients in the community after Proportion of the 149 isolates with resistance-associated mutations for a specifi c newer or repurposed antituberculosis drug (at least one nsSNP or structural variant in any gene related to the mechanism of action of the drug). Genes analysed are listed in the appendix (p 12). 60 (58%) of 104 isolates were from patients discharged home; of those, 3/60 (5%) were resistant to bedaquiline, 3/60 (5%) to delamanid, 7/60 (12%) to clofazimine, and 47/60 (78%) to rifabutin. ns=non-synonymous. SNP=single nucleotide polymorphism. *Pre-extensively drug-resistant tuberculosis isolates from patient taken within 3 months of a subsequent extensively drug-resistant tuberculosis diagnosis. Percentage of isolates with a structural variant or nsSNP in a resistance-associated region B discharge was 15·2 months (IQR 8·7-33·3), and 20 remained living in the community at the censor date. 17 (19%) patients were discharged home and living in the community before the diagnosis of 20 patients with extensively drug-resistant tuberculosis and highly similar genomic sequences (ie, ≤5 SNPs diff erent, and identical resistance-encoding mutations for 14 drugs), suggesting community-based transmission. The median time between home discharge and diagnosis of a secondary case was 9·2 months (IQR 5·4-9·7), and 11 (55%) of the 20 possible secondary cases were HIV-infected. 12 (60%) of these secondary cases had unfavourable outcomes and ten (50%) had died by the end of the study. The cough aerosol sampling technology became available only towards the end of the study period. 26 smear-positive individuals underwent cough aerosol sampling system to assess their degree of infectiousness.
One (4%) patient of 26 was cured, with the remaining 25 (96%) patients having unfavourable outcomes. 22 (85%) patients were home discharged with 11 (42%) living in the community at the time of testing. Six (23%) had positive cough aerosol cultures in the less than 5 μm respirable range and thus were highly infectious (appendix p 27). All six had an unfavourable outcome (four with treatment failure) and fi ve of these six (19%) were discharged home. One secondary case thought to have arisen from a home-discharged patient was cough aerosol sampling system-positive. Phenotypic drug susceptibility testing showed resistance to an average of six of 11 drugs in 20 (77%) sputum culture isolates acquired at the time of cough aerosol sampling system (six isolates were culture negative or contaminated). 13 patients who underwent cough aerosol sampling self-reported contact with other individuals, with a median of fi ve contacts per day (IQR 3·2-7·3) and a face mask not being worn for 458/610 (75%) of these interactions (appendix p 27). RFLP data were available for three contact pairs (appendix p 27) and were suggestive of transmission in each case.
Discussion
To our knowledge, this study is the fi rst prospective longterm report on the outcomes and infectiousness of patients with extensively drug-resistant tuberculosis in whom treatment had failed, and hence in patients with programmatically incurable tuberculosis. Overall, unfavourable outcomes occurred in 203 (74%) patients, with 67 (33%) of these individuals having failed treatment. 172 (63%) of all 273 patients in our study were discharged back into the community and 104 (60%) of these 172 patients had an unfavourable outcome. Although such patients are perceived to be terminally ill, in reality the proportion of patients who had survived at 12 months after discharge was 21% (57 of 273). Continued treatment was a post-discharge predictor of mortality, although we believe this fi nding to be an analytical artifact due to selection bias (with those who were the sickest and with most extensive disease being more likely to receive treatment).
Our data demonstrate that uncured survivors with extensively drug-resistant tuberculosis have considerable longevity in the community, not dissimilar to the prechemotherapeutic era when time to death occurred over years and roughly 20-30% of patients had chronic active disease. 40 By contrast, we previously reported an overall survival rate of about 70% in home-discharged patients in whom treatment had failed in a retrospectively selected follow-up cohort, possibly refl ecting selection and survival bias in that study.
14 High rates of treatment failure in extensively drug-resistant tuberculosis have been described in several tuberculosis-endemic countries, [14] [15] [16] 18 and substantial patient longevity and transmission from home-discharged patients within the community is likely to be occurring in such settings (although this has not yet been formally reported). In this study, both individuals with HIV infection and those without HIV infection were aff ected; multicentre studies are required to assess the global scale of this problem.
As demonstrated by cough aerosol sampling, six (23%) home-discharged patients assessed were highly infectious and a substantial proportion were smear positive. Culturepositive cough aerosols in the respirable range are the best predictor of recent tuberculosis infection (tuberculin skin test conversion), and subsequent development of active tuberculosis in household contacts, 35, 37 although this method has limited scalability and potential as a public health intervention in view of its technical complexity, cost, time to result (6-8 weeks) , and lack of portability (large, non-mobile equipment). We also noted high interperson contact scores and suboptimal mask usage among home-discharged patients.
We previously documented possible transmission from a single patient discharged home after treatment failure, causing a secondary case of extensively drug-resistant tuberculosis, in a retrospectively selected follow-up cohort.
14 Here, we demonstrate that 17 (19%) homedischarged patients with extensively drug-resistant tuberculosis might have caused a secondary case. One of the prerequisites for inferring such transmission was the absence of concurrent treatment at the same health-care facility (ie, the index cases of extensively drug-resistant tuberculosis were in the community before diagnosis of the secondary cases). This fi gure could be an underestimate, because it includes only secondary cases with development of active disease during the study period. Extended follow-up would be required to assess latently infected individuals who might progress to disease at a later date. Thus, transmission of extensively drugresistant tuberculosis from programmatically incurable patients discharged home is not uncommon. The mortality rate in secondary cases was substantial (50%), and we reiterate the urgent need to establish communitybased containment strategies. These strategies should include voluntary long-term community stay facilities and palliative care; 41 few such amenities exist in tuberculosis-endemic settings.
We did whole-genome sequencing (using a threshold of fi ve SNPs and matching drug-resistance markers) to study the molecular epidemiology of tuberculosis transmission. Although there are some drawbacks with the use of whole-genome sequencing to infer person-toperson transmission, it is a well accepted approximation. 30, 31 Investigators of previous studies have justifi ed the use of a fi ve-SNP threshold, showing its high predictive value to infer transmission. 42, 43 However, any threshold needs to be context-specifi c and related to mutation rate. Previously reported M tuberculosis mutation rates have varied between roughly 0·25 and 0·75 SNPs per genome per year in longitudinally sampled isolates from patients who were on antituberculosis treatment. 30 The median number of SNPs accumulated per isolate genome per year, 0·99 (95 CI 0·79-1·67), translates into a fi ve-SNP change (using the lower confi dence limit) occurring over 38 months; this fi gure is considerably more than the median duration of the diagnostic time diff erence between any two patients with extensively drug-resistant tuberculosis in our study of 14·1 months (IQR 6·4-23·3). Thus, although the use of SNP thresholds to infer resistance is contentious, we chose a conservative threshold of fi ve SNPs, and additionally required that isolates had identical mutations in all resistance-encoding genes. When we omitted the requirement for identical resistance mutations, 100 (71%) of 141 isolates shared fi ve or fewer SNP diff erences with at least one other isolate, compared with 65 (46%) of 141 isolates when this requirement was included in the analysis. Our estimates are therefore likely to be robust and have predictive value for inferring transmission.
We present evidence of transmission of extensively drug-resistant tuberculosis in that 65 (46%) isolates had negligible genetic diff erences compared with at least one other patient isolate. This fi nding suggests that transmission is not uncommon in this setting. This situation is not unique to South Africa; reports from China suggest that almost half of extensively drugresistant tuberculosis is due to primary transmission. 42 Access to rapid molecular technologies, and newer and repurposed drugs such as bedaquiline, delamanid, and linezolid, are urgently needed in tuberculosis-endemic countries. South Africa has a programme that off ers these drugs to a small number of patients, but they are not available to most patients in tuberculosis-endemic countries. Moreover, some individuals are denied access to these agents because of high-grade resistance that precludes the construction of an eff ective regimen. Although bedaquiline and linezolid are probably good choices to include in regimens against extensively drugresistant tuberculosis in this population, resistance to the nitroimidazoles is currently being reported, and treatment failures are already emerging. Findings from a 2016 multicentre study of a bedaquiline-based regimen showed that 38% of patients with extensively drug-resistant tuberculosis had not culture converted by 30 months after treatment. 44 Thus, there is and will continue to be a growing population of incurable tuberculosis cases in the community, underscoring the need for appropriate containment facilities to curtail transmission. Strategies to preserve new drugs should include prevention of pharmacokinetic mismatch and measures to ensure adherence.
In this context, a fi nding worthy of further investigation is the susceptibility to rifabutin of some rifampicinresistant strains. Although tentative, some data 45 suggest that treatment of multidrug-resistant tuberculosis with rifabutin in appropriate patients improves outcomes compared with the use of conventional regimens. Additionally, more than 90% of isolates did not have mutations associated with resistance to linezolid, bedaquiline, or delamanid. A regimen with these agents could reduce mortality and infectiousness but, although approved for clinical use, these drugs are often inaccessible in tuberculosis-endemic countries; there is urgent need to accelerate rollout to where they are most needed.
There were several limitations to this study. We followed up outcomes in patients with extensively drugresistant tuberculosis who were admitted to hospital and receiving treatment, thus selection bias and survival bias might have aff ected the fi ndings. However, during the period of this study local policy was to admit all patients diagnosed with extensively drug-resistant tuberculosis, which would have (if anything) underestimated poor outcomes because patients not diagnosed and thus not placed on treatment were not captured. However, these fi ndings may be less generalisable to settings with low prevalence of HIV coinfection. Indeed, we recruited all the patients in only two provinces of South Africa; in other provinces such as KwaZulu-Natal HIV co-infection rates are considerably higher. Other limitations include missing data due to default and loss to follow-up, and the fact that cause of death was not ascertained. Few patient isolates underwent extended phenotypic drug susceptibility testing and whole-genome sequencing; however, these isolates were only accessible from the Western Cape province, where 91% (186/204) of isolates underwent extended drug susceptibility testing and 75% (153/204) underwent whole-genome sequencing. We were unable to present conclusive geospatial linkages between patients due to logistical constraints given the sheer burden of disease in this setting. Although we did identify clusters of active disease within friend and family groups, we did not comprehensively and actively screen all contacts for disease (which is currently not done within the national tuberculosis programme). However, in patients with demonstrated geospatial linkages, isolate genomes were very similar. Inadequate access to compounds for phenotypic drug susceptibility testing, lack of consensus about cutpoints, and incomplete knowledge of genotypic markers for resistance to the new and repurposed drugs precluded a full assessment of susceptibility to these drugs. Almost half of the patients tested with cough aerosol sampling who were discharged home after treatment failure were highly infectious.
In conclusion, treatment failure of extensively drugresistant tuberculosis, and hence programmatically incurable tuberculosis, is a nascent but growing phenomenon. Using innovative tools we have demonstrated that substantial numbers of patients with highly drug-resistant and infectious tuberculosis are being discharged into the community after treatment failure and could be generating secondary cases of incurable tuberculosis. Data about these patients are vital to inform resource allocation and interventional strategies to contain this epidemic. Better approaches, including individualised treatment directed by whole-genome sequencing, 46 use of eff ective regimens containing new and repurposed drugs, prevention of the amplifi cation of resistance through optimal dosing and adherence promotion, and identifi cation of the most infectious patients for transmission interruption strategies are urgently needed.
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